Month: February 2026

LEADING EDGE MATERIALS’ PROGRESS UPDATE ON ROMANIAN EXPLORATION PROJECT2025 exploration campaign identifies significant areas of mineralisation underground in Valea Leucii, Dibarz and Avram Iancu, and wider potential across the exploration licence. Underground development mapping and sampling data reveal extensive mineralisation. Potential exists for mineralisation between Valea Leucii, Dibarz, and Avram Iancu to be connected, giving a mineralised zone extending approximately 6 kilometres north–south and a similar distance east–west.Vancouver, 2 February 2026 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) provides an update on its exploration activities in Romania and latest assay results. Key Findings from 2025 CampaignMapping and sampling...

Hexagon Purus ASA’s fourth quarter results 2025 will be released on 10 February 2026, 07:00 CET. Morten Holum (CEO) and Salman Alam (CFO) will present the results at 08:30 CET and the presentation will be broadcasted live via https://hexagonpurus.vivida.live. The presentation will be held in English and will be virtual. A recording of the presentation will be made available on www.hexagonpurus.com. For more information: Mathias Meidell, IR Director, Hexagon Purus ASATelephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com Salman Alam, CFO, Hexagon Purus ASA Telephone: +47 476 12 713 | salman.alam@hexagonpurus.com About Hexagon Purus ASA Hexagon Purus enables zero emission mobility for a cleaner energy future. The company is a world leading provider of hydrogen Type 4 high-pressure cylinders and systems, battery systems and...

N Very strong Q4 2025 at +5.9% Confident in delivering a 7th year of outperformance in 2026 February 3, 2026+5.9% Q4 organic growth, leading to +5.6% in 2025 Solid FY performance across all regions: U.S. at +5.2%, Europe +4.2% and APAC at +5.8% Industry-leading financial KPIs:18.2% operating margin rate, up 20 basis points year-on-year Headline EPS of €7.48, up 6.6% at constant currency Free cash flow1 at €2.0 billion, up 10.6% 2025 proposed dividend at €3.75 per share, up 4.2%, fully paid in cashExpect to outperform again for 7th consecutive year in 2026: Full year organic growth guidance of +4% to +5% Improving best-in-class financial ratios in 2026:Operating margin rate slightly above 18.2% Free cash flow1 at c. €2.1 billion2FY 2025 results  2025 2025 vs 2024Net organic growth3 +5.6%  Operating margin rate 18.2% +20bps  2025 2025...

 Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, February 3, 2026 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in Molecular Psychiatry1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) could be transformative in the treatment of anxiety and fear-related disorders, such as post-traumatic stress disorder (PTSD). In the study, scientists from the Center for Psychiatric Neurosciences (CNP, CHUV/UNIL) in Lausanne, Switzerland, evaluated the effects of ADX71743, a highly selective mGlu7 NAM, in established models of fear learning...

Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease Introduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program 2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth) 2026 total operating expense guidance of US$330 – US$335 million Investor Day will be webcast today starting at 10:00 am EST (16:00 CET)Leiden, The Netherlands, February 3, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced 2026 financial guidance and will highlight its advancing clinical-stage rare disease pipeline, including two major value-creating programs, at a virtual Investor Day taking place later today. The...

eQ Plc Stock Exchange Release 3 February 2026 at 8:00 AM eQ is renewing the composition of its Management Team to support the implementation of the strategy and the management of the Group. eQ’s Board of Directors has appointed the Group’s Management Team and the new Management Team will start its work on 3 February 2026 under the leadership of CEO Jouko Pölönen. Composition of the Management Team from 3 February 2026:Jouko Pölönen, CEO of eQ Plc, M.Sc. (Econ.), EMBA (born 1970) Tero Estovirta, CEO of eQ Asset Management Ltd, M.Sc. (Tech.) (born 1971) Jacob af Forselles, CEO of Advium Corporate Finance Oy, M.Sc. (Econ.), LL.B (born 1973) Kirsi Hokka, Customer Relations, M. Sc. (Econ) (born 1965) Taina Kyllönen, Human Resources and Communications, M.Sc. (Econ.) (born 1967) Arimo Leppä, Technology and Development, LL.M. (born 1984) Antti...

eQ Plc Stock Exchange Release3 February 2026, at 8:15 am Notice of the Annual General Meeting Notice is given to the shareholders of eQ Plc to the Annual General Meeting (the “AGM”) to be held on 24 March 2026 at 5:00 p.m. at Sanoma House’s Eliel meeting room, Töölönlahdenkatu 2, 00100 Helsinki, Finland. The reception of persons who have registered for the meeting will commence at 4:30 p.m. at the meeting venue. The AGM will be held as a hybrid meeting in accordance with chapter 5, section 16, subsection 2 of the Finnish Limited Liability Companies Act. As an alternative to participating in the Annual General Meeting at the meeting venue, shareholders can fully exercise their rights during the meeting also via remote connection. Shareholders can exercise their right to vote also by voting in advance. Further attendance instructions, instructions...